Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 127 participants.

Also called NCT05983770

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 127 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05983770
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Australia, Brazil, Canada, France, Germany, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05983770. Randomized; no masking; primary purpose treatment. Start 2023-08-30 (actual); primary completion 2025-09-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
Condition
Kidney Transplant Rejection
Intervention (Drug)
AT-1501
Intervention (Drug)
Tacrolimus
Lead sponsor
Eledon Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct05983770
Content hash
ebc395ca4be706d25518da01b6fe71281f3b28ee62be5d7b50fe5577d2aa742f